Bios Life Exits Stealth With $25M for Cancer Surveillance

Fundraise Insider tracks newly funded startups each week and delivers verified sales leads of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Bios Life came out of stealth on August 10, 2026 with $25 million in a Seed round led by Redmile, Vsquared Ventures and Kindred Capital. Healthcare and technology investors from both the United States and Europe filled out the round.

The Boston company is building an AI native cancer surveillance business, which in practice means a virtual clinic for cancer survivors and other people carrying elevated risk. The premise is that periodic screening leaves long gaps, and that continuous monitoring built on clinical, laboratory and genomic information can close them.

Two partnerships give the model its data. Bios Life has agreed to use de identified oncology datasets from Tempus to train and validate its predictive models, and it is folding genetic screening from Ambry Genetics into the service itself.

Ryan Richardson, formerly chief strategy officer at BioNTech, co founded the company. The US platform is set to launch in the second half of 2026, with a waitlist already open.

Continuous monitoring has been a long standing ambition in healthcare, and survivorship care is one of the few areas where the clinical case and the commercial case point the same direction. The Massachusetts company will have to prove the predictions hold up.

Companies selling into hospitals, payers and provider groups can reach verified contacts at newly funded health startups through Healthcare Sales Leads.